News
In the Phase III DeLLphi-304 trial, patients with small cell lung cancer administered Imdelltra achieved a statistically ...
GlobalData on MSN17h
Mural shuts down lead programme and slashes 90% of staffMural Oncology is halting development of its lead IL-2 therapy and enacting major layoffs after its second trial failure this ...
Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.
Zacks.com on MSN15h
MURA Soars as it Explores Strategic Options Post Cancer Study FailuresMural Oncology stock skyrockets after it begins exploring strategic alternatives to maximize shareholder value after the failure of two cancer studies for nemvaleukin alfa.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback